PhD Programme in Biomedical Sciences, Medical Faculty, Universitas Indonesia, Jakarta, Indonesia.
Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.
Malar J. 2021 Apr 9;20(1):177. doi: 10.1186/s12936-021-03709-y.
A goal of malaria epidemiological interventions is the detection and treatment of parasite reservoirs in endemic areas-an activity that is expected to reduce local transmission. Since the gametocyte is the only transmissible stage from human host to mosquito vector, this study evaluated the pre and post presence of gametocytes during a mass screening and treatment (MST) intervention conducted during 2013 in East Nusa Tenggara, Indonesia.
RT-qPCR targeting pfs25 and pvs25 transcripts-gametocyte molecular markers for Plasmodium falciparum and Plasmodium vivax, respectively, was performed to detect and quantify gametocytes in blood samples of P. falciparum and P. vivax-infected subjects over the course of the MST study. The presence of both asexual and sexual parasites in microscopic and submicroscopic infections was compared from the start and end of the MST, using proportion tests as well as parametric and non-parametric tests.
Parasite prevalence remained unchanged for P. falciparum (6% = 52/811 versus 7% = 50/740, p = 0.838), and decreased slightly for P. vivax (24% = 192/811 versus 19% = 142/740, p = 0.035) between the MST baseline and endpoint. No significant difference was observed in gametocyte prevalence for either P. falciparum (2% = 19/803 versus 3% = 23/729, p = 0.353, OR = 1.34, 95%CI = 0.69-2.63), or P. vivax (7% = 49/744 versus 5% = 39/704, p = 0.442, OR = 0.83, 95%CI = 0.52-1.31). Even though there was an insignificant difference between the two time points, the majority of parasite positive subjects at the endpoint had been negative at baseline (P. falciparum: 66% = 29/44, P. vivax: 60% = 80/134). This was similarly demonstrated for the transmissible stage-where the majority of gametocyte positive subjects at the endpoint were negative at baseline (P. falciparum: 95% = 20/21, P. vivax: 94% = 30/32). These results were independent of treatment provided during MST activities. No difference was demonstrated in parasite and gametocyte density between both time points either in P. falciparum or P. vivax.
In this study area, similar prevalence rates of P. falciparum and P. vivax parasites and gametocytes before and after MST, although in different individuals, points to a negligible impact on the parasite reservoir. Treatment administration based on parasite positivity as implemented in the MST should be reevaluated for the elimination strategy in the community. Trial registration Clinical trials registration NCT01878357. Registered 14 June 2013, https://www.clinicaltrials.gov/ct2/show/NCT01878357.
疟疾流行病学干预的目标之一是检测和治疗流行地区的寄生虫库——这一活动有望减少当地传播。由于配子体是人类宿主向蚊媒传播的唯一可传播阶段,因此本研究评估了在 2013 年印度尼西亚东努沙登加拉进行的大规模筛查和治疗(MST)干预前后配子体的存在情况。
针对恶性疟原虫和间日疟原虫的 pfs25 和 pvs25 转录本-配子体分子标志物,使用 RT-qPCR 检测和定量血液样本中的配子体在 MST 研究过程中。使用比例检验以及参数和非参数检验,比较了微镜和亚显微镜感染中无性和有性寄生虫的存在情况,从 MST 的开始和结束。
恶性疟原虫的寄生虫患病率保持不变(6%=52/811 与 7%=50/740,p=0.838),间日疟原虫的患病率略有下降(24%=192/811 与 19%=142/740,p=0.035)在 MST 基线和终点之间。恶性疟原虫(2%=19/803 与 3%=23/729,p=0.353,OR=1.34,95%CI=0.69-2.63)和间日疟原虫(7%=49/744 与 5%=39/704,p=0.442,OR=0.83,95%CI=0.52-1.31)的配子体患病率均无显著差异。尽管两个时间点之间存在无统计学差异,但终点时大多数寄生虫阳性患者在基线时为阴性(恶性疟原虫:66%=29/44,间日疟原虫:60%=80/134)。这同样适用于可传播阶段-终点时大多数配子体阳性患者在基线时为阴性(恶性疟原虫:95%=20/21,间日疟原虫:94%=30/32)。这些结果独立于 MST 活动期间提供的治疗。在恶性疟原虫或间日疟原虫中,两个时间点的寄生虫和配子体密度均无差异。
在本研究地区,MST 前后恶性疟原虫和间日疟原虫寄生虫和配子体的患病率相似,尽管在不同个体中,但对寄生虫库的影响可以忽略不计。应根据寄生虫阳性情况重新评估 MST 中实施的治疗管理,以制定社区消除策略。
试验注册 临床试验注册 NCT01878357。于 2013 年 6 月 14 日注册,https://www.clinicaltrials.gov/ct2/show/NCT01878357。